Tingyu Wang
YOU?
Author Swipe
View article: Platelet Hyperactivation Plays a Critical Role in Exacerbating Skin Lesions in Rats with Psoriasis and Blood Stasis Syndrome
Platelet Hyperactivation Plays a Critical Role in Exacerbating Skin Lesions in Rats with Psoriasis and Blood Stasis Syndrome Open
Psoriasis with BSS rats exhibit more severe skin lesions than psoriasis rats, associated with enhanced platelet activation. Clopidogrel improved blood stasis and skin inflammation, confirming that platelet activation contributes critically…
View article: Deep Learning‐Based Prediction of High‐Risk Gastroesophageal Varices Using Two‐Dimensional Shear Wave Elastography
Deep Learning‐Based Prediction of High‐Risk Gastroesophageal Varices Using Two‐Dimensional Shear Wave Elastography Open
Aims Bleeding from gastroesophageal varices (GEV) is a medical emergency associated with high mortality. We aim to construct an artificial intelligence‐based model of two‐dimensional shear wave elastography (2D‐SWE) of the liver and spleen…
View article: Targeting sphingosine-1-phosphate receptor 1 alleviates neuropathic pain associated with pancreatic ductal adenocarcinoma in mice and inhibits tumor progression
Targeting sphingosine-1-phosphate receptor 1 alleviates neuropathic pain associated with pancreatic ductal adenocarcinoma in mice and inhibits tumor progression Open
Background: Pancreatic neuropathy occurs during the development of pancreatic ductal adenocarcinoma (PDAC), with changes correlating to pancreatic neuropathic pain and increased expression of nociceptive genes in sensory ganglia. Emerging …
View article: Study on the Evolution and Predictive for Coordinated Development of Regional Water Resources, Economic Society, and Ecological Environment
Study on the Evolution and Predictive for Coordinated Development of Regional Water Resources, Economic Society, and Ecological Environment Open
Water resources are strategic resources that support regional economic social development and maintain the health and stability of ecosystems. This study revealed the evolution of the coordinated development of China’s water resources–econ…
View article: Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US
Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US Open
Background Chronic lymphocytic leukaemia (CLL) is considerably more common in Americans compared with Asians. The bases for these differences and implications for therapy outcomes are controversial and mostly unknown. Methods We compared b…
View article: Comparative responsive patterns of Opisthopappus taihangensis and Opisthopappus longilobus under salt stress by weighted gene co-expression network analysis (WGCNA) and genome-wide association studies (GWAS)
Comparative responsive patterns of Opisthopappus taihangensis and Opisthopappus longilobus under salt stress by weighted gene co-expression network analysis (WGCNA) and genome-wide association studies (GWAS) Open
View article: Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 5. Factors associated with progression.
View article: Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 6. The outcomes and disease status of patients who completed the treatment.
View article: Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 6. Swim lane plots of efficacy in patients treated with ZID.
View article: Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 4. Change of lymphocyte subsets before and after treatment.
View article: Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Inclusion and exclusion criteria, Exclusion criteria, Treatment termination criteria and exclusion criteria, Case exclusion criteria, General combined medication and supportive care
View article: Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 1. Schematic diagram of the research scheme.
View article: Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 2. Treatment flow chart.
View article: Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 4. Factors associated with deep response rate after induction and at best response.
View article: Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 5. Survival outcomes in patients with or without deep remission.
View article: Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 3. Mutations and immunoglobulin heavy chain variable (IGHV) fragments of patients.
View article: Supplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplementary Table 1. Representativeness of Study Participants.
View article: Supplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 2.The modified criteria from IWWM-6.
View article: Supplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 3.The results of chromosome karyotype in all the patients.
View article: Data from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Data from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Purpose:Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. Bruton’s tyrosine kinase inhibitors have shown promising outcomes, yet achieving deep remission (very good partial remission or complete remi…
View article: Dysregulated homocysteine metabolism and cardiovascular disease and clinical treatments
Dysregulated homocysteine metabolism and cardiovascular disease and clinical treatments Open
View article: Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma Open
View article: Identification and expression responses of TCP gene family in Opisthopappus taihangensis under abiotic stress
Identification and expression responses of TCP gene family in Opisthopappus taihangensis under abiotic stress Open
The TCP gene family plays pivotal roles in the development and abiotic stress responses of plants; however, no data has been provided for this gene family in Opisthopappus taihangensis . Based on O. taihangensis genome, 14 TCP genes were i…
View article: The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma Open
Recent advances in measurable residual disease (MRD) technology have significantly enhanced predictive accuracy for outcomes in various hematologic malignancies, serving as a crucial surrogate endpoint. However, in mantle cell lymphoma (MC…
View article: Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study
Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study Open
Background/Aims: A large percentage of patients undergoing esophagogastroduodenoscopy (EGD) screening do not have esophageal varices (EV) or have only small EV. We evaluated a large, international, multicenter cohort to develop a novel sco…
View article: Effects of advanced glycation end products on stem cell
Effects of advanced glycation end products on stem cell Open
In recent years, stem cell therapy has become a pivotal component of regenerative medicine. Stem cells, characterized by their self-renewal capacity and multidirectional differentiation potential, can be isolated from a variety of biologic…
View article: Supplementary Figure S1 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
Supplementary Figure S1 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia Open
Supplementary Figure 1. Mutation rates of MYD88 in patients with different tumor load detected by (A) Sanger sequencing; (B) next generation sequencing (NGS); (C) real-time allele specific polymerase chain reaction (AS-PCR); (D) droplet di…
View article: Supplementary Table S10 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
Supplementary Table S10 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia Open
Supplementary Table 10. The response rate by MYD88/CXCR4 genotype during first-line BTKi-based therapy.
View article: Supplementary Figure S8 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
Supplementary Figure S8 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia Open
Supplementary Figure 8. The survival outcomes of patients with MYD88/CXCR4 mutation status according to the option of different first-line therapies. The progression free survival and overall survival in patients with cytotoxic therapy (A-…
View article: Supplementary Figure S5 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
Supplementary Figure S5 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia Open
Supplementary Figure 5. The IGHV-D-J gene repertoire between CXCR4 mutated and wild type groups. (A) Distribution of major VH family gene segments; (B) Distribution of major DH family gene segments; (C) Distribution of major JH family gene…